Research programme: transforming growth factor beta-1 receptor antagonists - Biogen IdecAlternative Names: SM-16
Latest Information Update: 24 Feb 2011
At a glance
- Originator Biogen Idec
- Class Small molecules
- Mechanism of Action Transforming growth factor beta1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer